Telomir Pharmaceuticals Inc. (TELO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.94 (-3.01% 1D, market cap $71.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TELO ranks #716 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TELO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and MAIA (MAIA Biotechnology Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $72.9M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while LFVN leads on capital efficiency (29.2% ROIC).
Per TELO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971532), Telomir Pharmaceuticals Inc. generated $0 in revenue, -$10.4M in net income, and -$3.7M in free cash flow against $7.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 29.3 (OVERSOLD (<32))
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While TELO currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($0.99) forces dealer call-delta covering toward $1.66.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Telomir Pharmaceuticals Inc. (TELO) dropped -3.01% to $0.94, trading at 19% of its 52-week range ($0.79 – $1.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
GlobeNewswire report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
The Business Journals report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
AllSci report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TELO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TELO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Telomir Pharmaceuticals Inc. (TELO) ranks #716 by composite RQD confidence (34/100, grade E) and #704 by equity capitalization ($71.0M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with TELO at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TELO
ACTIVE
Telomir Pharmaceuticals Inc. | E | 34/100 | — | — | -35.0% | -3.01% | $71.0M | Benchmark Subject |
| TENX Tenax Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -3.76% | $69.6M | /tenx-vs-telo → |
| MAIA MAIA Biotechnology Inc. | D | 48/100 | — | — | -35.0% | -6.78% | $72.9M | /maia-vs-telo → |
| MNOV Medicinova Inc | E | 30/100 | 5.7x | — | -35.0% | 0.00% | $68.9M | /mnov-vs-telo → |
| LFVN Lifevantage Corporation (Delaware) | B+ | 76/100 | 7.5x | 80.4% | 29.2% | +0.17% | $73.9M | /lfvn-vs-telo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Telomir Pharmaceuticals Inc. (TELO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.4M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (+27.3% YoY). On the balance sheet, TELO closed FY2025 with $7.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$10.4M | -$3.7M | -$3.7M | $7.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$16.5M | -$5.1M | -$5.1M | $1.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$13.1M | -$3.9M | -$3.9M | — | — |
As of 2026-11-02, Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.94 (-3.01% 1D, market cap $71.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TELO ranks #716 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TELO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and MAIA (MAIA Biotechnology Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $72.9M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while LFVN leads on capital efficiency (29.2% ROIC).
Per TELO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971532), Telomir Pharmaceuticals Inc. generated $0 in revenue, -$10.4M in net income, and -$3.7M in free cash flow against $7.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
TELO last traded at $0.94 (-3.01% on volume of 96,701 shares), positioning the stock -16.81% below its 50-day simple moving average ($1.13) and -22.95% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.79 to $1.58, TELO sits at the 19.0% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).
Why TELO Stock dropped -3.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, TELO scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is built from five pillars, each out of 20. The fundamental cash engine scores 6/20, reflecting an ROIC of -35% and an FCF yield of -5.19%; for an investor, this pillar signals that the business is currently consuming rather than generating cash relative to its market value. Whale 13F flow scores 7/20 for institutional accumulation and options positioning, indicating limited institutional support in the source data. Insider conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar, suggesting insiders and disclosed officials are not signaling confidence through their trades. Macro regime fit scores 8/20 with a beta of 1.0, meaning the stock moves in line with the broader market and offers no defensive cushion. Forensic balance sheet scores 10/20, combining an Altman Z of 2.5, a Piotroski F of 3/9, and a debt-to-equity ratio of 0.5; this is the strongest pillar but still indicates weak financial quality. Taken together, a prospective investor should view the upside case as dependent on a catalyst-driven recovery rather than on present cash generation, with valuation risk, dilution risk, and sustained losses as the primary tradeoffs.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $0.0M | $-10.4M | N/A | $-3.7M | N/A | N/A |
| FY 2024 | $0.0M | $0.0M | $-16.5M | N/A | $-5.1M | $1.3M | N/A |
| FY 2023 | $0.0M | $0.0M | $-13.1M | N/A | $-3.9M | N/A | N/A |
Per the SEC financials, the company reported net losses in each of the three periods, with no reported revenue or operating income, and gross, operating, and net margins all shown as 0%. Per the market data section, ROIC is -35%, and per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and the debt-to-equity ratio is 0.5. The balance sheet posture is described in the source as forensic-risk-flagged, with cash reported only for FY 2024 at $1.3M and debt not available in source data for any period.
Per the recent news section, the dominant event is a $5.6M financing reported across multiple outlets, with coverage describing a PIPE transaction and placement agent warrants. A news item states that billionaire entrepreneur John Paul DeJoria increased his investment in the company, which is tagged as a market-wire item. Several items are tagged as catalysts tied to a breast cancer trial, including reporting that the proceeds are intended to advance Telomir-Zn into a Phase I/II TNBC trial. Other items are tagged as market-wire coverage of seasonal return charts and institutional positioning, with one report referencing a $1 million additional bet by a Patrón co-founder. Risk watch items include the dilution implicit in a PIPE with placement agent warrants and the reliance on financing to fund ongoing losses. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Telomir Pharmaceuticals Inc. (TELO) • Click "Debate This Headline" to argue it in the Roar Pit below
GlobeNewswire report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Mugglehead Investment Magazine report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
The Business Journals report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
AllSci report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Dealroom report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Telomir Pharmaceuticals Inc. (TELO) market action, institutional positioning, and fundamental catalysts.
Welcome to the TELO (Telomir Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on TELO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Telomir Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on TELO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.96 (52-wk range $0.90 - $1.11), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).